In Brief This Week: Cepheid; BD; Transgenomic; Synthetic Genomics; Genetic Technologies; BioTime; Kiyatec; ABL | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid this week received CE marking for its Xpert CT/NG and Xpert CT tests, and the firm said it would begin shipping the tests in Europe immediately. The tests are for rapid detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhea and run on Cepheid's GeneXpert System.


The Board of Directors of Becton Dickinson has declared a quarterly dividend of $.45 per share. The dividend is payable on June 29 to shareholders of record on June 8.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.